ANTIBODY-DRUG CONJUGATE COMPRISING ANTIBODY AGAINST HUMAN ROR1, AND USE FOR THE SAME

The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, Sung Min, YANG, Young-Jae, PARK, Kyungjin, KIM, Hyoung Rae, YEOM, Donghoon, BAEK, Ju Yuel, PARK, Minji, RYU, Hyun Min, CHAE, Jeiwook, SONG, Daehae, SUNG, Byungje, JUNG, Jinwon, LEE, Yangsoon, KANG, Dae Hyuck, HAN, Nara, PARK, Yun Hee, LEE, Chang Sun, YOU, Ji-Na, LEE, Bora, EOM, Jaehyun, AHN, Jinhyung, PARK, Kyung Eun, KIM, Yong Zu, YOO, Jiseon, KIM. Juhee, HONG, Youngeun, OH, Ji Hye, LEE, Ju Young, LEE, Hyeun Joung, SONG, Ho Young
Format Patent
LanguageEnglish
French
German
Published 22.11.2023
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
Bibliography:Application Number: EP20200861806